Business ❯ Pharmaceuticals

Acquisitions

Sanofi Novartis Market Trends Biotechnology Bristol Myers Squibb Drug Development AbbVie Market Strategy Corporate Strategy Rare Diseases Pfizer BioNTech Merck Clinical Trials Genmab AstraZeneca Vertex Pharmaceuticals Cancer Treatment Cancer Treatments Market Valuation Genetics Eli Lilly Genetic Testing Biopharmaceuticals Ophthalmology Biontech Data Privacy Merck Group Market Dynamics JB Chemicals Biopharmaceutical Companies Psychedelic Treatments Biotech Companies Clinical Development Biopharma Industry Weight Loss Drugs Partnerships Biogen Merus Strategic Partnerships Novo Nordisk Regulatory Approval Company History Zydus Lifesciences Organon & Co COVID-19 Impact Corporate Finance Competition Private Equity Biopharma Obesity Treatments Icosavax Acquisition Icosavax First Wave BioPharma Inc AstraZeneca PLC

Novartis to Buy Avidity for $12 Billion in Cash at $72 a Share

The deal advances Novartis’s rare-disease strategy through Avidity’s muscle-targeted RNA platform.

Alkermes to Buy Avadel in Up to $2.1 Billion Deal With CVR Tied to Lumryz Expansion

Bristol Myers Squibb Buys Orbital Therapeutics for $1.5 Billion to Push In Vivo CAR‑T Into Autoimmune Care

Novo Nordisk to Acquire Akero for Up to $5.2 Billion to Expand in MASH

Pfizer to Buy Metsera in Up to $7.3 Billion Obesity Bet